GlassScriptPhysician profile
Philippe Vaillancourt
NPI 1801861976
$10,944.59
in general payments reported to CMS, 2019-2025
57 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,543 · 2020: $1,123 · 2021: $2,823 · 2022: $3,085 · 2023: $1,046 · 2024: $181 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.45 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,247.79 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Biogen, INC. | $844.32 | 2019-2023 | Tysabri, Vumerity |
| Lundbeck LLC | $700.63 | 2019-2023 | Vyepti |
| Amgen INC. | $698.26 | 2019-2024 | Uplizna |
| Allergan, INC. | $626.14 | 2019-2022 | |
| Emd Serono, INC. | $459.74 | 2019-2023 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $436.06 | 2019-2023 | Austedo |
| Neurelis, INC. | $405.47 | 2021-2022 | |
| Harmony Biosciences LLC | $392.73 | 2021-2023 | Wakix |
| Neurocrine Biosciences, INC. | $340.49 | 2019-2023 | Ingrezza, Ongentys |
| Collegium Pharmaceutical, INC. | $330.71 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $310.95 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $298.98 | 2019-2022 | |
| Horizon Therapeutics Plc | $286.73 | 2021-2022 | |
| Adamas Pharmaceuticals, INC. | $262.49 | 2019-2021 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philippe Vaillancourt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.